AU2008201044B2 - Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers - Google Patents
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers Download PDFInfo
- Publication number
- AU2008201044B2 AU2008201044B2 AU2008201044A AU2008201044A AU2008201044B2 AU 2008201044 B2 AU2008201044 B2 AU 2008201044B2 AU 2008201044 A AU2008201044 A AU 2008201044A AU 2008201044 A AU2008201044 A AU 2008201044A AU 2008201044 B2 AU2008201044 B2 AU 2008201044B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- cancer cells
- protein
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Novel genes designated and set forth in Figure 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table 1. Consequently, of gene products of a gene of Figure 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of Figure 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of Figure 2 can be used in active or passive immunization.
Description
Editorial Note Case #2008201044 This specification totals more than 1000 pages. Please contact IP Australia if you wish to obtain a copy.
Claims (13)
- 2. A method of treating or preventing cancer in a subject wherein said cancer comprises cancer cells expressing a protein comprising an amino acid sequence of SEQ ID NO:34, and wherein said method comprises administering to the subject a therapeutically effective amount of an antibody or fragment thereof that immunospecifically binds to an epitope of the amino acid sequence of SEQ ID NO: 34 on said protein to inhibit growth of cancer cells expressing said protein in the subject.
- 3. Use of an antibody or fragment thereof that immunospecifically binds an epitope of a protein having an amino acid sequence set forth in SEQ ID NO: 34 to inhibit growth of one or more cancer cells expressing a protein comprising an amino acid sequence of SEQ ID NO:34.
- 4. Use of an antibody or fragment thereof that immunospecifically binds an epitope of a protein having an amino acid sequence set forth in SEQ ID NO: 34 to treat or prevent cancer in a subject by inhibiting growth of cancer cells expressing a protein comprising an amino acid sequence of SEQ ID NO:34 in said subject.
- 5. Use an antibody or fragment thereof that immunospecifically binds an epitope of a protein having an amino acid sequence set forth in SEQ ID NO: 34 in the manufacture of a medicament for treating or preventing cancer by inhibiting growth of a one or more cancer cells expressing a protein comprising an amino acid sequence of SEQ ID NO:34 in a subject.
- 6. The method according to claim 1 or the use according to any one of claims 3 to 5 wherein the cancer cells are selected from the group consisting of prostate cancer cells, bladder cancer cells, kidney cancer cells, colon cancer cells, lung cancer cells, ovary cancer cells, breast cancer cells, pancreas cancer cells, testis cancer cells, rectum cancer cells, cervix cancer cells, stomach cancer cells and uterus cancer cells. 627
- 7. The method according to claim 2 or the use according to any one of claims 3 to 5, wherein the cancer is selected from the group consisting of prostate cancer, bladder cancer, kidney cancer, colon cancer, lung cancer, ovary cancer, breast cancer, pancreas cancer, testis cancer, rectum cancer, cervix cancer, stomach cancer and uterus cancer.
- 8. The method according to any one of claims 1, 2, 6 or 7 or the use according to any one of claims 3 to 7, wherein the antibody or fragment thereof is conjugated with a cytotoxic agent.
- 9. The method or use of claim 8, wherein the cytotoxic agent is selected from the group consisting of one or more radioactive isotopes, one or more chemotherapeutic agents and one or more toxins.
- 10. The method or use of claim 9, wherein the radioactive isotopes are selected from the group consisting of .. 1 At, 1311, 125j, 90 Y, ' 86 Re, ' 88 Re, 153 Sm, 212 Bi, 32 P and radioactive isotopes of Lu.
- 11. The method or use of claim 9, wherein the chemotherapeutic agents are selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.
- 12. The method or use of claim 9, wherein the toxins are selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.
- 13. The method or use according to any one of claims 1 to 12, wherein the antibody or fragment thereof is monoclonal.
- 14. The method according to any one of claims 1, 2 or 6 to 13 or the use according to any one of claims 3 to 13 substantially as herein described with reference to any one or more of the accompanying drawings and/or examples. 628 Dated this TWENTY SECOND day of JUNE, 2011 AGENSYS, INC. Patent Attorneys for the Applicant: FB Rice 629
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008201044A AU2008201044B2 (en) | 2001-04-10 | 2008-03-05 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/282,739 | 2001-04-10 | ||
| US60/283,112 | 2001-04-10 | ||
| US60/286,630 | 2001-04-25 | ||
| PCT/US2002/011654 WO2002083921A2 (en) | 2001-04-10 | 2002-04-10 | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| AU2002318112A AU2002318112B2 (en) | 2001-04-10 | 2002-04-10 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| AU2008201044A AU2008201044B2 (en) | 2001-04-10 | 2008-03-05 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002318112A Division AU2002318112B2 (en) | 2001-04-10 | 2002-04-10 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008201044A1 AU2008201044A1 (en) | 2008-04-03 |
| AU2008201044B2 true AU2008201044B2 (en) | 2011-07-28 |
Family
ID=39294276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008201044A Ceased AU2008201044B2 (en) | 2001-04-10 | 2008-03-05 | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2008201044B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109801646B (en) * | 2019-01-31 | 2021-11-16 | 嘉楠明芯(北京)科技有限公司 | Voice endpoint detection method and device based on fusion features |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998032853A2 (en) * | 1997-01-24 | 1998-07-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1999058660A1 (en) * | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
| WO1999063088A2 (en) * | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
-
2008
- 2008-03-05 AU AU2008201044A patent/AU2008201044B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998032853A2 (en) * | 1997-01-24 | 1998-07-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1999058660A1 (en) * | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
| WO1999063088A2 (en) * | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008201044A1 (en) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Songsivilai et al. | Bispecific antibody: a tool for diagnosis and treatment of disease | |
| Pai et al. | Treatment of advanced solid tumors with immunotoxin LMB–1: an antibody linked to Pseudomonas exotoxin | |
| Palitzsch et al. | A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer | |
| RU2008152332A (en) | ANTIBODIES RECOGNIZING THE CARBOHYDRATE EPITOP ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS, AND METHODS OF APPLICATION | |
| CA2395053A1 (en) | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof | |
| JP2005520566A5 (en) | ||
| WO2001005427B1 (en) | Psca: prostate stem cell antigen and uses thereof | |
| JP2009197002A5 (en) | ||
| JP2009539380A5 (en) | ||
| HUT63204A (en) | Process for producing monoclonal antibodies against human tumor necrosis alpha-factor | |
| JP2007526880A5 (en) | ||
| JP2006500009A5 (en) | ||
| EP1232186A2 (en) | Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin | |
| US20230295346A1 (en) | Prodruggable antibodies, prodrugs thereof, and methods of use and making | |
| Imakiire et al. | Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen | |
| WO2016022939A1 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
| JP2005505256A5 (en) | ||
| Harris et al. | Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59 | |
| NZ596981A (en) | Compositions and methods for the treatment of tumor of hematopoietic origin | |
| CN1056084C (en) | Immunotoxins directed against CD33 related surface antigens | |
| AU2008201044B2 (en) | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | |
| AU2019219937B2 (en) | Anti-TRAILR2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy | |
| Akamatsu et al. | A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. | |
| CN101864398B (en) | Monoclonal antibody of anti-gonadotropin-releasing hormone receptor and application thereof | |
| WO2003104429B1 (en) | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |